NL-OMON35545
Completed
N/A
A RANDOMIZED, DOUBLE-BLIND DRUG-DRUG INTERACTION STUDY TO ASSESS THE EFFECT OF DS-5565 ON THE PHARMACOKINETICS, PHARMACODYNAMICS AND SAFETY AND TOLERABILITY OF ETHANOL, AND VICE VERSA IN HEALTHY SUBJECTS - DS-5565 Ethanol interaction study
Daiichi Pharmaceutical0 sites16 target enrollmentTBD
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- (zenuw)pijn bij diabetis en bij herpes (koortslip)
- Sponsor
- Daiichi Pharmaceutical
- Enrollment
- 16
- Status
- Completed
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Healthy male and female (negative pregnancy test)
- •age: 18\-55 years (inclusive)
- •BMI: 19\.0 \- 30\.0 (inclusive)
- •Moderate alcohol consumption; 7\-21 units (males) or 5\-14 units (females) of alcohol per week
Exclusion Criteria
- •Suffering from: hepatitis B, cancer or HIV/Aids. In case of participation in another drug study within 60 days before the start of this study or being a blood donor within 60 days from the start of the study. In case of donating more than 1\.5 liters blood in the 10 months preceding the start of the study.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, Not Recruiting
Phase 1
This is a study to Evaluate the Safety and Efficacy of ABBV-154 in Subjects with Moderately to Severely Active Crohn's Disease (CD)Subjects with moderately to severely active Crohn's diseaseMedDRA version: 20.0Level: PTClassification code 10011401Term: Crohn's diseaseSystem Organ Class: 10017947 - Gastrointestinal disordersTherapeutic area: Diseases [C] - Immune System Diseases [C20]EUCTR2021-002869-18-BEAbbVie Deutschland GmbH & Co. KG265
Active, Not Recruiting
Phase 1
Clinical Trial to compare if seriously-ill adults with constipation due to narcotics have bowel movements sooner after injection with Methylnatrexone or placeboEUCTR2007-000854-30-BESalix Pharmaceuticals Inc254
Active, Not Recruiting
N/A
A study to evaluate the effect and safety of a 4 week treatment plan of Alirocumab in patients with high cholesterolPrimary HypercholesterolemiaMedDRA version: 17.0Level: LLTClassification code 10020604Term: HypercholesterolemiaSystem Organ Class: 100000004861Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]EUCTR2013-002343-29-GBRegeneron Pharmaceuticals, Inc.803
Active, Not Recruiting
N/A
A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Tolerability of E5555, and its Effects on Markers of Intravascular Inflammation in Subjects with Coronary Artery Disease - E5555-G000-201Coronary Artery DiseaseMedDRA version: 8.1Level: PTClassification code 10011078EUCTR2005-006029-94-BEEisai Limited720
Completed
N/A
A Randomized, Double-Blind, Placebo-Controlled Study in Healthy Male Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Oral Doses of JNJ-26070109abdominal pain and heartburn10017943NL-OMON30044Janssen-Cilag82